Stay updated on Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The page’s footer revision/version number has been updated from v3.5.2 to v3.5.3, indicating a site release or template update without substantive changes to the clinical trial information.
    Difference
    0.0%
    Check dated 2026-04-24T05:51:24.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    Page revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:37:36.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    Administrative metadata such as last update dates and submission history was refreshed; no core study details, eligibility criteria, or outcomes appear to have changed.
    Difference
    0.2%
    Check dated 2026-04-02T15:40:35.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    A new page revision label v3.5.0 was added, replacing the previous v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-19T06:09:30.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-11T23:57:01.000Z thumbnail image
  8. Check
    65 days ago
    Change Detected
    Summary
    Branding and attribution elements were added to the page footer, including references to Moffitt Cancer Center and helpful links. No study details or navigation were modified.
    Difference
    0.1%
    Check dated 2026-03-04T23:44:36.000Z thumbnail image

Stay in the know with updates to Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.